DDInter596 DDInter484
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Doxorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) EPHB2
EPHB2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) CCNA1
CCNA1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) binds {v} (Gene) NDUFS2
NDUFS2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) TSKU
TSKU {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) DRAP1
DRAP1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Doxorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Doxorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Doxorubicin (Compound) downregulates ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound)
Doxorubicin (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound by Dasatinib (Compound)
Doxorubicin (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Dasatinib (Compound)
Doxorubicin (Compound) binds NDUFS2 (Gene) and NDUFS2 (Gene) is upregulated by Dasatinib (Compound)
Doxorubicin (Compound) downregulates TSKU (Gene) and TSKU (Gene) is upregulated by Dasatinib (Compound)
Doxorubicin (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Dasatinib (Compound)
Doxorubicin (Compound) upregulates DRAP1 (Gene) and DRAP1 (Gene) is downregulated by Dasatinib (Compound)
Doxorubicin (Compound) binds TOP2A (Gene) and Doxorubicin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is downregulated by Dasatinib (Compound)